CA2987155A1 - Hpv vaccines - Google Patents
Hpv vaccines Download PDFInfo
- Publication number
- CA2987155A1 CA2987155A1 CA2987155A CA2987155A CA2987155A1 CA 2987155 A1 CA2987155 A1 CA 2987155A1 CA 2987155 A CA2987155 A CA 2987155A CA 2987155 A CA2987155 A CA 2987155A CA 2987155 A1 CA2987155 A1 CA 2987155A1
- Authority
- CA
- Canada
- Prior art keywords
- arenavirus
- viral vector
- protein
- antigen
- hpv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 75
- 241000712891 Arenavirus Species 0.000 claims abstract description 1026
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 230
- 238000000034 method Methods 0.000 claims abstract description 168
- 208000015181 infectious disease Diseases 0.000 claims abstract description 138
- 241000700605 Viruses Species 0.000 claims abstract description 132
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 99
- 231100000590 oncogenic Toxicity 0.000 claims abstract description 62
- 230000002246 oncogenic effect Effects 0.000 claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 48
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 16
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 16
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 16
- 239000013603 viral vector Substances 0.000 claims description 561
- 108700026244 Open Reading Frames Proteins 0.000 claims description 396
- 239000000427 antigen Substances 0.000 claims description 333
- 108091007433 antigens Proteins 0.000 claims description 333
- 102000036639 antigens Human genes 0.000 claims description 333
- 108090000288 Glycoproteins Proteins 0.000 claims description 225
- 102000003886 Glycoproteins Human genes 0.000 claims description 223
- 102000011931 Nucleoproteins Human genes 0.000 claims description 210
- 108010061100 Nucleoproteins Proteins 0.000 claims description 210
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 210
- 210000004027 cell Anatomy 0.000 claims description 165
- 108090000623 proteins and genes Proteins 0.000 claims description 159
- 239000012634 fragment Substances 0.000 claims description 153
- 102000004169 proteins and genes Human genes 0.000 claims description 150
- 239000002773 nucleotide Substances 0.000 claims description 138
- 125000003729 nucleotide group Chemical group 0.000 claims description 138
- 230000000890 antigenic effect Effects 0.000 claims description 125
- 230000002458 infectious effect Effects 0.000 claims description 109
- 150000001413 amino acids Chemical group 0.000 claims description 108
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 102
- 239000013598 vector Substances 0.000 claims description 93
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 89
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 84
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 76
- 230000010076 replication Effects 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 75
- 230000002950 deficient Effects 0.000 claims description 74
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 66
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 53
- 230000002519 immonomodulatory effect Effects 0.000 claims description 52
- 241000712890 Junin mammarenavirus Species 0.000 claims description 50
- 108020001507 fusion proteins Proteins 0.000 claims description 48
- 102000037865 fusion proteins Human genes 0.000 claims description 48
- 150000007523 nucleic acids Chemical group 0.000 claims description 45
- 239000002299 complementary DNA Substances 0.000 claims description 44
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 claims description 38
- 241000699670 Mus sp. Species 0.000 claims description 38
- 101710132595 Protein E7 Proteins 0.000 claims description 36
- 239000013612 plasmid Substances 0.000 claims description 35
- 101710132594 Protein E6 Proteins 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 33
- 230000002163 immunogen Effects 0.000 claims description 30
- 230000003612 virological effect Effects 0.000 claims description 30
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 24
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 230000027455 binding Effects 0.000 claims description 23
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 claims description 21
- 230000035772 mutation Effects 0.000 claims description 21
- 102000004082 Calreticulin Human genes 0.000 claims description 19
- 108090000549 Calreticulin Proteins 0.000 claims description 19
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 19
- 241000711549 Hepacivirus C Species 0.000 claims description 19
- 241000701022 Cytomegalovirus Species 0.000 claims description 18
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 17
- 230000006798 recombination Effects 0.000 claims description 17
- 238000005215 recombination Methods 0.000 claims description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 16
- 230000028327 secretion Effects 0.000 claims description 16
- 239000011701 zinc Substances 0.000 claims description 16
- 229910052725 zinc Inorganic materials 0.000 claims description 16
- 230000005867 T cell response Effects 0.000 claims description 14
- 230000002068 genetic effect Effects 0.000 claims description 14
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 13
- 102100039793 E3 ubiquitin-protein ligase RAG1 Human genes 0.000 claims description 12
- 241000700721 Hepatitis B virus Species 0.000 claims description 12
- 101000744443 Homo sapiens E3 ubiquitin-protein ligase RAG1 Proteins 0.000 claims description 12
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 11
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 11
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 11
- 241000579048 Merkel cell polyomavirus Species 0.000 claims description 11
- 108090000848 Ubiquitin Proteins 0.000 claims description 11
- 102000044159 Ubiquitin Human genes 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 206010059313 Anogenital warts Diseases 0.000 claims description 10
- 108020004635 Complementary DNA Proteins 0.000 claims description 10
- 208000000907 Condylomata Acuminata Diseases 0.000 claims description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 10
- 230000002238 attenuated effect Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 201000010153 skin papilloma Diseases 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 8
- 108060003393 Granulin Proteins 0.000 claims description 8
- 108060004795 Methyltransferase Proteins 0.000 claims description 8
- 241001672814 Porcine teschovirus 1 Species 0.000 claims description 8
- 101710132637 Protein C2 Proteins 0.000 claims description 8
- 101710132593 Protein E2 Proteins 0.000 claims description 8
- 101710132611 Protein E3 Proteins 0.000 claims description 8
- 101710132596 Protein E4 Proteins 0.000 claims description 8
- 101710132597 Protein E5 Proteins 0.000 claims description 8
- 101710132697 Protein L2 Proteins 0.000 claims description 8
- 102000017143 RNA Polymerase I Human genes 0.000 claims description 8
- 108010013845 RNA Polymerase I Proteins 0.000 claims description 8
- 102000009572 RNA Polymerase II Human genes 0.000 claims description 8
- 108010009460 RNA Polymerase II Proteins 0.000 claims description 8
- 241001648840 Thosea asigna virus Species 0.000 claims description 8
- 101710195626 Transcriptional activator protein Proteins 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 108010029697 CD40 Ligand Proteins 0.000 claims description 7
- 102100032937 CD40 ligand Human genes 0.000 claims description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 7
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 7
- 239000013566 allergen Substances 0.000 claims description 7
- 239000005090 green fluorescent protein Substances 0.000 claims description 7
- 108010028930 invariant chain Proteins 0.000 claims description 7
- 108010077753 type II interferon receptor Proteins 0.000 claims description 7
- 208000007514 Herpes zoster Diseases 0.000 claims description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 6
- 208000037581 Persistent Infection Diseases 0.000 claims description 6
- 230000002457 bidirectional effect Effects 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 6
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 claims description 5
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 5
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 5
- 239000000854 Human Growth Hormone Substances 0.000 claims description 5
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 5
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 claims description 4
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 claims description 4
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 4
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 4
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
- 206010034299 Penile cancer Diseases 0.000 claims description 4
- 206010047741 Vulval cancer Diseases 0.000 claims description 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
- 208000000260 Warts Diseases 0.000 claims description 4
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims description 4
- 201000004201 anogenital venereal wart Diseases 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 102000034287 fluorescent proteins Human genes 0.000 claims description 4
- 108091006047 fluorescent proteins Proteins 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 201000006958 oropharynx cancer Diseases 0.000 claims description 4
- 108010054624 red fluorescent protein Proteins 0.000 claims description 4
- 206010046885 vaginal cancer Diseases 0.000 claims description 4
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 4
- 201000005102 vulva cancer Diseases 0.000 claims description 4
- 206010038707 Respiratory papilloma Diseases 0.000 claims description 3
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000010415 tropism Effects 0.000 claims description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 15
- 101710132701 Protein L1 Proteins 0.000 claims 6
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 3
- 101710192266 Tegument protein VP22 Proteins 0.000 claims 3
- 210000003705 ribosome Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 abstract description 29
- 201000010099 disease Diseases 0.000 abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
- 238000011282 treatment Methods 0.000 abstract description 27
- 230000001613 neoplastic effect Effects 0.000 abstract description 21
- 230000002265 prevention Effects 0.000 abstract description 18
- 238000009169 immunotherapy Methods 0.000 abstract description 5
- 201000010536 head and neck cancer Diseases 0.000 abstract description 3
- 208000014829 head and neck neoplasm Diseases 0.000 abstract description 3
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 2
- 101000798665 Rhizobium etli (strain CFN 42 / ATCC 51251) Acyl carrier protein AcpXL Proteins 0.000 description 76
- 101000786191 Acinetobacter calcoaceticus Uncharacterized protein in pqq-V 5'region Proteins 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 31
- 101000961724 Pseudanabaena tenuis (strain PCC 7409) Uncharacterized phycocyanin operon protein Z Proteins 0.000 description 24
- 238000010186 staining Methods 0.000 description 18
- 108700005077 Viral Genes Proteins 0.000 description 17
- 210000003771 C cell Anatomy 0.000 description 16
- 238000002255 vaccination Methods 0.000 description 16
- 238000011740 C57BL/6 mouse Methods 0.000 description 15
- 210000005259 peripheral blood Anatomy 0.000 description 15
- 239000011886 peripheral blood Substances 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000249107 Teschovirus A Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 102000046157 human CSF2 Human genes 0.000 description 6
- 230000008707 rearrangement Effects 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241001244466 New world arenaviruses Species 0.000 description 4
- 241001244462 Old world arenaviruses Species 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 102000045222 parkin Human genes 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 2
- 108010029973 Lymphocytic choriomeningitis virus glycoprotein peptide Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000585245 Methylophaga aminisulfidivorans Species 0.000 description 2
- 101000793654 Mus musculus Calreticulin Proteins 0.000 description 2
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101500024857 Mus musculus Ubiquitin Proteins 0.000 description 2
- 101500025138 Mus musculus Ubiquitin Proteins 0.000 description 2
- 101500026511 Mus musculus Ubiquitin Proteins 0.000 description 2
- 101500027538 Mus musculus Ubiquitin Proteins 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229960001714 calcium phosphate Drugs 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- 241000190711 Amapari mammarenavirus Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241001440626 Bear Canyon mammarenavirus Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000190598 Flexal mammarenavirus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 241000555269 Ippy mammarenavirus Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000190596 Latino mammarenavirus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000712898 Machupo mammarenavirus Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000555271 Mobala mammarenavirus Species 0.000 description 1
- 241000712897 Mopeia mammarenavirus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000146363 Oliveros mammarenavirus Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000190594 Parana mammarenavirus Species 0.000 description 1
- 241000712910 Pichinde mammarenavirus Species 0.000 description 1
- 241000245926 Pirital mammarenavirus Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000192617 Sabia mammarenavirus Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000712908 Tacaribe mammarenavirus Species 0.000 description 1
- 241000190592 Tamiami mammarenavirus Species 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000205658 Whitewater Arroyo mammarenavirus Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000009803 radical hysterectomy Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000010159 squamous cell papilloma Diseases 0.000 description 1
- 208000017015 squamous papilloma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173805P | 2015-06-10 | 2015-06-10 | |
| US62/173,805 | 2015-06-10 | ||
| US201562254410P | 2015-11-12 | 2015-11-12 | |
| US62/254,410 | 2015-11-12 | ||
| US201662331158P | 2016-05-03 | 2016-05-03 | |
| US62/331,158 | 2016-05-03 | ||
| PCT/EP2016/063182 WO2016198531A2 (en) | 2015-06-10 | 2016-06-09 | Hpv vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2987155A1 true CA2987155A1 (en) | 2016-12-15 |
Family
ID=56137292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2987155A Pending CA2987155A1 (en) | 2015-06-10 | 2016-06-09 | Hpv vaccines |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10669315B2 (enExample) |
| EP (1) | EP3307308A2 (enExample) |
| JP (2) | JP7098330B2 (enExample) |
| CN (2) | CN107921117B (enExample) |
| AU (2) | AU2016274655B2 (enExample) |
| CA (1) | CA2987155A1 (enExample) |
| HK (1) | HK1246183A1 (enExample) |
| WO (1) | WO2016198531A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221475T3 (hr) | 2007-12-27 | 2023-01-06 | Universität Zürich | Replikacijski defektni vektori arenavirusa |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| LT3077519T (lt) | 2013-12-03 | 2021-04-26 | Hookipa Biotech Gmbh | Cmv vakcinos |
| RS60937B1 (sr) | 2014-11-13 | 2020-11-30 | Univ Geneve | Tri-segmentirani arenavirusi kao vektori za vakcinu |
| JP7098330B2 (ja) | 2015-06-10 | 2022-07-11 | ホオキパ バイオテック ジーエムビーエイチ | Ｈｐｖワクチン |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| ES2934698T3 (es) | 2015-11-04 | 2023-02-24 | Hookipa Biotech Gmbh | Vacunas contra el virus de la hepatitis B |
| CA3003548A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| EP3534943A2 (en) * | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| WO2018185307A1 (en) * | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
| EP3652325A4 (en) * | 2017-07-14 | 2021-09-15 | Oncorus, Inc. | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| KR102222582B1 (ko) * | 2018-02-02 | 2021-03-04 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
| CN109706144A (zh) * | 2018-03-07 | 2019-05-03 | 江苏润洁生物科技有限公司 | 一种治疗性hpv核酸疫苗 |
| EP3880812A4 (en) * | 2018-11-13 | 2022-09-07 | Oncorus, Inc. | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE |
| JP7688576B6 (ja) * | 2018-11-28 | 2025-07-04 | ザ ジェネラル ホスピタル コーポレイション | 共生ウイルスに対するｔ細胞指向性抗がんワクチン |
| JP7125760B2 (ja) * | 2019-06-14 | 2022-08-25 | 国立研究開発法人理化学研究所 | 免疫系を賦活化する細胞および当該細胞を含む医薬組成物 |
| AU2020297011A1 (en) * | 2019-06-18 | 2022-02-10 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof |
| US20220380805A1 (en) * | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| JPWO2021095838A1 (enExample) * | 2019-11-15 | 2021-05-20 | ||
| KR20230011335A (ko) * | 2020-05-14 | 2023-01-20 | 이노비오 파마수티컬즈, 인크. | 재발성 호흡기 유두종증에 대한 백신 및 이의 사용 방법 |
| AU2021282287A1 (en) | 2020-05-29 | 2023-01-05 | Hookipa Biotech Gmbh | Cancer treatment strategies using arenavirus vectors |
| US20240174724A1 (en) | 2021-03-23 | 2024-05-30 | Hookipa Biotech Gmbh | Arenaviruses used in treatments of prostate cancer |
| CN115820696A (zh) * | 2022-07-28 | 2023-03-21 | 怡道生物科技(苏州)有限公司 | 治疗性多价HPV mRNA疫苗及其制备方法 |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| WO2025155938A1 (en) * | 2024-01-18 | 2025-07-24 | Aov Biopharma, Inc. | Vaccine for prevention and treatment of human papilloma virus related cancer |
| WO2025191169A1 (en) * | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
| CN118344491B (zh) * | 2024-05-03 | 2025-02-14 | 华中科技大学同济医学院附属同济医院 | 一种hpv16/18治疗性疫苗、制备方法和应用 |
| CN118599010B (zh) * | 2024-05-03 | 2025-06-27 | 武汉凯德基诺生物技术有限公司 | 一种hpv16/18/52治疗性疫苗、制备方法和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US6869779B1 (en) * | 1998-08-27 | 2005-03-22 | Fuso Pharmaceutical Industries, Ltd. | Nucleic acid sequence for potentiating the expression of useful gene and method therefor |
| DK1185615T3 (da) * | 1999-04-06 | 2007-11-05 | Wisconsin Alumni Res Found | Rekombinante influenzavirus til vacciner og genterapi |
| BR0314529A (pt) * | 2002-10-03 | 2005-08-09 | Wyeth Corp | Polipeptìdeos de papilomavìrus humano e composições imunogênicas |
| AP2007004020A0 (en) * | 2004-11-30 | 2007-06-30 | Aeras Global Tb Vaccine Found | Bacterial packaging strains useful for generation and production of recombinant double stranded rna nucleocapsids |
| EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| HRP20221475T3 (hr) | 2007-12-27 | 2023-01-06 | Universität Zürich | Replikacijski defektni vektori arenavirusa |
| CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| IN2014DN06118A (enExample) | 2012-01-24 | 2015-08-14 | Sanford Res Usd | |
| WO2013151731A1 (en) * | 2012-04-02 | 2013-10-10 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium for induction of cellular immune response |
| US8999925B2 (en) * | 2013-02-26 | 2015-04-07 | The Administrators Of The Tulane Educational Fund | Arenavirus inhibiting peptides and uses therefor |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| LT3077519T (lt) | 2013-12-03 | 2021-04-26 | Hookipa Biotech Gmbh | Cmv vakcinos |
| WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| JP6875274B6 (ja) | 2014-09-22 | 2021-06-30 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ピチンデウイルスのリバースジェネティクス系及び使用方法 |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| RS60937B1 (sr) * | 2014-11-13 | 2020-11-30 | Univ Geneve | Tri-segmentirani arenavirusi kao vektori za vakcinu |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| JP7098330B2 (ja) | 2015-06-10 | 2022-07-11 | ホオキパ バイオテック ジーエムビーエイチ | Ｈｐｖワクチン |
| ES3021881T3 (en) | 2015-10-23 | 2025-05-27 | Pasteur Institut | Recombinant mopeia virus and vaccine platform |
| ES2934698T3 (es) | 2015-11-04 | 2023-02-24 | Hookipa Biotech Gmbh | Vacunas contra el virus de la hepatitis B |
| CA3003548A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| US10980877B2 (en) | 2016-04-28 | 2021-04-20 | The University Of Chicago | Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen |
| KR20240095333A (ko) | 2016-05-18 | 2024-06-25 | 유니버시타트 바셀 | 백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스 |
| EP3534943A2 (en) | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
| AU2020297011A1 (en) * | 2019-06-18 | 2022-02-10 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| AU2021282287A1 (en) | 2020-05-29 | 2023-01-05 | Hookipa Biotech Gmbh | Cancer treatment strategies using arenavirus vectors |
-
2016
- 2016-06-09 JP JP2017563914A patent/JP7098330B2/ja active Active
- 2016-06-09 CA CA2987155A patent/CA2987155A1/en active Pending
- 2016-06-09 US US15/580,964 patent/US10669315B2/en active Active
- 2016-06-09 CN CN201680046208.4A patent/CN107921117B/zh active Active
- 2016-06-09 WO PCT/EP2016/063182 patent/WO2016198531A2/en not_active Ceased
- 2016-06-09 EP EP16730302.3A patent/EP3307308A2/en active Pending
- 2016-06-09 CN CN202210614772.9A patent/CN115197965A/zh active Pending
- 2016-06-09 AU AU2016274655A patent/AU2016274655B2/en active Active
- 2016-06-09 HK HK18105733.1A patent/HK1246183A1/zh unknown
-
2020
- 2020-04-30 US US16/863,456 patent/US11407790B2/en active Active
-
2021
- 2021-09-13 AU AU2021232660A patent/AU2021232660B2/en active Active
-
2022
- 2022-06-29 US US17/853,783 patent/US20230086859A1/en not_active Abandoned
- 2022-06-29 JP JP2022104300A patent/JP2022160401A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115197965A (zh) | 2022-10-18 |
| JP7098330B2 (ja) | 2022-07-11 |
| HK1246183A1 (zh) | 2018-09-07 |
| US20230086859A1 (en) | 2023-03-23 |
| US20210024584A1 (en) | 2021-01-28 |
| CN107921117B (zh) | 2022-06-07 |
| AU2021232660B2 (en) | 2025-02-27 |
| US20180179257A1 (en) | 2018-06-28 |
| AU2016274655A1 (en) | 2017-12-21 |
| CN107921117A (zh) | 2018-04-17 |
| US10669315B2 (en) | 2020-06-02 |
| JP2018518172A (ja) | 2018-07-12 |
| EP3307308A2 (en) | 2018-04-18 |
| WO2016198531A3 (en) | 2017-01-19 |
| AU2021232660A1 (en) | 2021-10-07 |
| AU2016274655B2 (en) | 2021-06-17 |
| WO2016198531A2 (en) | 2016-12-15 |
| US11407790B2 (en) | 2022-08-09 |
| JP2022160401A (ja) | 2022-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230086859A1 (en) | Hpv vaccines | |
| US11040096B2 (en) | Therapeutic HPV16 vaccines | |
| AU2014359276B2 (en) | CMV vaccines | |
| US10287323B2 (en) | Therapeutic HPV18 vaccines | |
| Michel et al. | Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination | |
| Daemen et al. | Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7 | |
| US20200123571A1 (en) | Compositions and Methods of Treatment | |
| US20070166328A1 (en) | Genetic immunization against cervical carcinoma | |
| JP2019514988A (ja) | 組合せプライム：ブースト療法 | |
| US20250066427A1 (en) | Therapeutic papilloma virus vaccines | |
| Jindra et al. | Attenuated recombinant influenza A virus expressing HPV16 E6 and E7 as a novel therapeutic vaccine approach | |
| US20050118139A1 (en) | Vaccine using papilloma virus e proteins delivered by viral vector | |
| HK40082300A (en) | Hpv vaccines | |
| US20250041399A1 (en) | Cmv-based human papillomavirus vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |
|
| EEER | Examination request |
Effective date: 20210527 |